Oasmia resolves on a rights issue of approximately SEK 399 million

NEXT STORY
Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors
PREV STORY
Bavarian Nordic Completes Enrollment of Phase 3 Lot-Consistency Trial of Freeze-dried Smallpox Vaccine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AroCell AB: Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017

AroCell AB (publ) announces today that the abstract entitled: "Quantification of cell loss in ...

author_avatar
NASDAQ Market News

Albireo Announces Bylvay® (odevixibat) Now Available in Germany

author_avatar
NASDAQ Market News

Publication in Annals of Internal Medicine® Reveals T2Bacteria® Panel as the First Direct-from-Blood, Non-Culture Test that Rapidly Diagnoses Bacterial Bloodstream Infections

author_avatar
NASDAQ Market News